Safety and Efficacy of Drug Combinations Against Schistosomiasis

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of MBD in combination with PZQ in the treatment of SCH and STH in children aged 1-15 years of age.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: DBL -Institute for Health Research and Development
• Treatments: Albendazole; DMP 777; Mebendazole; Piperazine; Piperazine citrate; Praziquantel

Criteria

Inclusion Criteria:

• Those with an age of 1-15 years of age

• Are infected with schistosomiasis and soil-transmitted helminthiasis

• Whose parent consent and who are willing to participate

Exclusion Criteria:

• Those with acute and chronic diseases other than schistosomiasis and soil-transmitted helminthiasis

• Those with a history of any serious adverse drug reactions